vs

Side-by-side financial comparison of LANTRONIX INC (LTRX) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.

RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($60.1M vs $29.8M, roughly 2.0× LANTRONIX INC). LANTRONIX INC runs the higher net margin — -4.5% vs -92.6%, a 88.1% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs -4.5%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs -15.0%).

Lantronix Inc is a global provider of secure IoT connectivity and edge computing solutions. It offers specialized hardware, SaaS platforms and embedded software for industrial, healthcare, retail, transportation and smart city clients worldwide, supporting reliable remote device management.

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

LTRX vs RYTM — Head-to-Head

Bigger by revenue
RYTM
RYTM
2.0× larger
RYTM
$60.1M
$29.8M
LTRX
Growing faster (revenue YoY)
RYTM
RYTM
+88.3% gap
RYTM
83.8%
-4.5%
LTRX
Higher net margin
LTRX
LTRX
88.1% more per $
LTRX
-4.5%
-92.6%
RYTM
Faster 2-yr revenue CAGR
RYTM
RYTM
Annualised
RYTM
43.8%
-15.0%
LTRX

Income Statement — Q2 FY2026 vs Q1 FY2026

Metric
LTRX
LTRX
RYTM
RYTM
Revenue
$29.8M
$60.1M
Net Profit
$-1.3M
$-55.6M
Gross Margin
43.6%
88.1%
Operating Margin
-3.6%
-87.1%
Net Margin
-4.5%
-92.6%
Revenue YoY
-4.5%
83.8%
Net Profit YoY
43.9%
EPS (diluted)
$-0.03
$-0.83

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LTRX
LTRX
RYTM
RYTM
Q1 26
$60.1M
Q4 25
$29.8M
$57.3M
Q3 25
$29.8M
$51.3M
Q2 25
$28.8M
$48.5M
Q1 25
$28.5M
$32.7M
Q4 24
$31.2M
$41.8M
Q3 24
$34.4M
$33.3M
Q2 24
$49.1M
$29.1M
Net Profit
LTRX
LTRX
RYTM
RYTM
Q1 26
$-55.6M
Q4 25
$-1.3M
$-47.5M
Q3 25
$-1.4M
$-52.9M
Q2 25
$-2.6M
$-46.6M
Q1 25
$-3.9M
$-49.5M
Q4 24
$-2.4M
$-43.3M
Q3 24
$-2.5M
$-43.6M
Q2 24
$386.0K
$-32.3M
Gross Margin
LTRX
LTRX
RYTM
RYTM
Q1 26
88.1%
Q4 25
43.6%
91.6%
Q3 25
44.8%
89.3%
Q2 25
40.0%
88.6%
Q1 25
43.5%
88.8%
Q4 24
42.6%
90.9%
Q3 24
42.1%
88.5%
Q2 24
38.1%
89.9%
Operating Margin
LTRX
LTRX
RYTM
RYTM
Q1 26
-87.1%
Q4 25
-3.6%
-82.2%
Q3 25
-5.1%
-102.6%
Q2 25
-10.9%
-93.4%
Q1 25
-12.6%
-143.7%
Q4 24
-6.9%
-98.6%
Q3 24
-6.2%
-132.0%
Q2 24
1.2%
-139.2%
Net Margin
LTRX
LTRX
RYTM
RYTM
Q1 26
-92.6%
Q4 25
-4.5%
-83.0%
Q3 25
-4.7%
-103.1%
Q2 25
-9.1%
-96.1%
Q1 25
-13.6%
-151.4%
Q4 24
-7.6%
-103.6%
Q3 24
-7.3%
-131.2%
Q2 24
0.8%
-110.9%
EPS (diluted)
LTRX
LTRX
RYTM
RYTM
Q1 26
$-0.83
Q4 25
$-0.03
$-0.73
Q3 25
$-0.04
$-0.82
Q2 25
$-0.06
$-0.75
Q1 25
$-0.10
$-0.81
Q4 24
$-0.06
$-0.71
Q3 24
$-0.07
$-0.73
Q2 24
$0.01
$-0.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LTRX
LTRX
RYTM
RYTM
Cash + ST InvestmentsLiquidity on hand
$23.0M
$340.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$74.4M
$122.9M
Total Assets
$121.7M
$442.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LTRX
LTRX
RYTM
RYTM
Q1 26
$340.6M
Q4 25
$23.0M
$388.9M
Q3 25
$22.2M
$416.1M
Q2 25
$20.1M
$291.0M
Q1 25
$20.0M
$314.5M
Q4 24
$19.2M
$320.6M
Q3 24
$26.4M
$298.4M
Q2 24
$26.2M
$319.1M
Stockholders' Equity
LTRX
LTRX
RYTM
RYTM
Q1 26
$122.9M
Q4 25
$74.4M
$139.1M
Q3 25
$74.5M
$148.8M
Q2 25
$74.4M
$-11.9M
Q1 25
$75.5M
$18.9M
Q4 24
$77.9M
$21.7M
Q3 24
$78.9M
$11.2M
Q2 24
$81.4M
$39.3M
Total Assets
LTRX
LTRX
RYTM
RYTM
Q1 26
$442.3M
Q4 25
$121.7M
$480.2M
Q3 25
$119.6M
$506.9M
Q2 25
$123.7M
$372.7M
Q1 25
$124.2M
$386.7M
Q4 24
$134.2M
$392.3M
Q3 24
$137.9M
$363.6M
Q2 24
$136.2M
$381.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LTRX
LTRX
RYTM
RYTM
Operating Cash FlowLast quarter
$2.2M
Free Cash FlowOCF − Capex
$2.1M
FCF MarginFCF / Revenue
7.0%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$9.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LTRX
LTRX
RYTM
RYTM
Q1 26
Q4 25
$2.2M
$-25.4M
Q3 25
$3.6M
$-26.6M
Q2 25
$1.1M
$-23.3M
Q1 25
$3.2M
$-40.4M
Q4 24
$340.0K
$-18.8M
Q3 24
$2.7M
$-25.2M
Q2 24
$2.3M
$-29.1M
Free Cash Flow
LTRX
LTRX
RYTM
RYTM
Q1 26
Q4 25
$2.1M
Q3 25
$3.5M
Q2 25
$909.0K
Q1 25
$3.1M
Q4 24
$256.0K
Q3 24
$2.5M
Q2 24
$2.1M
FCF Margin
LTRX
LTRX
RYTM
RYTM
Q1 26
Q4 25
7.0%
Q3 25
11.9%
Q2 25
3.2%
Q1 25
10.9%
Q4 24
0.8%
Q3 24
7.3%
Q2 24
4.3%
Capex Intensity
LTRX
LTRX
RYTM
RYTM
Q1 26
Q4 25
0.3%
Q3 25
0.2%
Q2 25
0.5%
Q1 25
0.4%
Q4 24
0.3%
Q3 24
0.5%
Q2 24
0.3%
Cash Conversion
LTRX
LTRX
RYTM
RYTM
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
5.89×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LTRX
LTRX

Embedded Io T Solutions$13.9M47%
Io T System Solutions$13.3M45%
Software And Services$2.6M9%

RYTM
RYTM

Segment breakdown not available.

Related Comparisons